Pernix Inks $101M Deal To Purchase Cypress Pharmaceuticals

Law360, Washington (November 14, 2012, 6:52 PM EST) -- Pediatric pharmaceutical company Pernix Therapeutics Holdings will purchase generic-drug maker Cypress Pharmaceuticals Inc. and its branded subsidiary Hawthorn Pharmaceuticals Inc. in a $101 million deal that will significantly increase its drug pipeline, the company announced Wednesday.

Under the terms of the deal, Pernix will pay $68.5 million in cash and $12.5 million in equity upfront for the Madison, Miss.-based drugmakers, with an additional $10 million to be paid in December 2013 and another $10 million available via milestone payments.

Commercial finance company MidCap Financial LLC will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.